{"url_path":"/sec/skye/8-k/2026-05-15/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-035535-index.html","accession_number":"0001628280-26-035535","cik":"0001516551","ticker":"SKYE","issuer_name":"Skye Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1516551/0001628280-26-035535-index.html","primary_entity_key":"0001516551","primary_entity_name":"Skye Bioscience, Inc."},"word_count":343,"has_tables":true,"body_markdown":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.\n\nOn May 13, 2026, Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the Company’s stockholders’ equity was $9,011,804, and therefore, the Company was not in compliance with Nasdaq Global Market’s Listing Rule 5450(b)(1)(A), which requires a $10,000,000 minimum stockholders’ equity standard. The Notice has no immediate effect on the listing or trading of the Company’s common stock, par value $0.001 per share (the “common stock”) on the Nasdaq Global Market and the common stock will continue to trade under the symbol “SKYE”.\n\nPursuant to Nasdaq Marketplace Rule 5810(c)(2)(C), the Company has been provided 45 calendar days, or until June 29, 2026, to supply a specific plan to regain compliance with all Nasdaq Global Market listing requirements and the Company’s time frame to complete its plan. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the Notice, or until November 9, 2026, to evidence compliance. If the plan is not accepted, the Company will have the right to appeal and the common stock would remain listed on The Nasdaq Global Market until the completion of the appeal process. To regain compliance, the Company must have stockholders’ equity of at least $10,000,000.\n\nThe Company is currently evaluating various alternative courses of action to regain compliance. There can be no assurance that the Company will be able to regain compliance with the minimum stockholders’ equity requirement or maintain compliance with the other listing requirements.\n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n                        SKYE BIOSCIENCE, INC.\n\n  \n\n  \n\nDated: May 15, 2026\n\n/s/  Punit Dhillon\n\n \nName: Punit Dhillon\n\n \nTitle: Chief Executive Officer"}